Autoimmune and inflammatory diseases
53 public biotech companies we cover are developing treatments for rheumatoid arthritis, lupus, Sjögren's disease, gout, transplant rejection and other immune conditions. 25 upcoming catalysts are listed below, with dates as the companies gave them.
Companies
- AbCellera Biologics (ABCL)Thesis Intact
Autoimmunity, Autoimmune disease
- Aclaris Therapeutics (ACRS)Thesis Intact
Immuno-inflammatory diseases
- Adaptive Biotechnologies (ADPT)Thesis Challenged
Ankylosing spondylitis
- Alumis (ALMS)Thesis Challenged
Sjögren's disease, Sjögren's syndrome, Systemic lupus erythematosus
- ANI Pharmaceuticals (ANIP)Thesis Challenged
Gouty arthritis, Rheumatoid arthritis, Acute gouty arthritis flares
- Aquestive Therapeutics (AQST)Thesis Challenged
Anaphylaxis
- Arcus Biosciences (RCUS)Thesis Intact
Rheumatoid arthritis, Systemic lupus erythematosus
- Artiva Biotherapeutics (ARTV)Thesis Intact
Sjögren disease, Systemic sclerosis, Rheumatoid arthritis
- Autolus Therapeutics (AUTL)Thesis Intact
Systemic lupus erythematosus
- Aytu BioPharma (AYTU)Thesis Challenged
Allergic rhinitis
- Biohaven (BHVN)Thesis Challenged
Rheumatoid arthritis
- C4 Therapeutics (CCCC)Thesis Intact
Inflammation
- Cabaletta Bio (CABA)Thesis Intact
Systemic sclerosis, Systemic lupus erythematosus
- Cartesian Therapeutics (RNAC)Thesis Intact
Antisynthetase syndrome, Chronic refractory gout
- Chemomab Therapeutics (CMMB)Thesis Challenged
Systemic sclerosis, Rheumatoid arthritis
- Climb Bio (CLYM)Thesis Intact
Autoimmune disease, Systemic lupus erythematosus
- Contineum Therapeutics (CTNM)Thesis Challenged
Fibrotic disease
- Coya Therapeutics (COYA)Thesis Intact
Inflammation, Inflammatory diseases
- CRISPR Therapeutics (CRSP)Thesis Intact
Autoimmune disease, Systemic sclerosis, Autoimmune encephalitis, Systemic lupus erythematosus
- Cullinan Therapeutics (CGEM)Thesis Intact
Sjogren's disease, Autoimmune diseases, Rheumatoid arthritis, Autoimmune cytopenias, and 1 more
- Eledon Pharmaceuticals (ELDN)Thesis Challenged
Islet cell transplantation
- Evaxion (EVAX)Thesis Intact
Autoimmune disease, Autoimmune diseases
- Immunovant (IMVT)Thesis Challenged
Sjögren's disease, Rheumatoid arthritis, Difficult-to-treat rheumatoid arthritis
- Immutep (IMMP)Thesis Challenged
Autoimmune disease
- InflaRx (IFRX)Thesis Intact
Anca-associated vasculitis
- Insight Molecular Diagnostics (IMDX)Thesis Challenged
Transplant rejection
- Jade Biosciences (JBIO)Thesis Intact
Rheumatoid arthritis
- Jasper Therapeutics (JSPR)Thesis Challenged
Autoantibody-mediated disorders, Severe combined immunodeficiency
- Kiniksa Pharmaceuticals International (KNSA)Thesis Intact
IL-1-mediated disease, IL-1-mediated diseases, Cryopyrin-associated periodic syndromes
- Kyverna Therapeutics (KYTX)Thesis Intact
Autoimmune disease, Rheumatoid arthritis
- Liquidia (LQDA)Thesis Intact
Systemic sclerosis-associated raynaud's phenomenon, Raynaud's phenomenon associated with systemic sclerosis (SSC-RP)
- Mesoblast (MESO)Thesis Intact
Steroid-refractory acute GVHD, Steroid-refractory acute graft versus host disease
- Monte Rosa Therapeutics (GLUE)Thesis Intact
Gout, Sjogren's disease, Immune-mediated diseases
- MoonLake Immunotherapeutics (MLTX)Thesis Intact
Psoriatic arthritis, Axial spondyloarthritis
- Nektar Therapeutics (NKTR)Thesis Intact
Inflammation, Autoimmune disease, Rheumatic disorders
- Omeros (OMER)Thesis Challenged
Complement-mediated disease
- Prime Medicine (PRME)Thesis Challenged
Chronic granulomatous disease
- Protalix BioTherapeutics (PLX)Thesis Intact
Gout, Uncontrolled gout, Neutrophil extracellular trap-related diseases
- Quoin Pharmaceuticals (QNRX)Thesis Intact
Scleroderma
- Recursion Pharmaceuticals (RXRX)Thesis Intact
Inflammatory disease
- Rocket Pharmaceuticals (RCKT)Thesis Intact
Leukocyte adhesion deficiency type i
- Roivant Sciences (ROIV)Thesis Intact
Sjögren disease, Sjogren's disease, Rheumatoid arthritis
- Sana Biotechnology (SANA)Thesis Challenged
B-cell mediated autoimmune disease
- Shattuck Labs (STTK)Thesis Intact
Inflammatory disease
- Silence Therapeutics (SLN)Thesis Intact
Complement-mediated disease
- Soligenix (SNGX)Thesis Broken
Behçet's Disease
- Tectonic Therapeutic (TECX)Thesis Intact
Fibrotic disease
- TG Therapeutics (TGTX)Thesis Intact
Autoimmune diseases (non-MS)
- Tiziana Life Sciences (TLSA)Thesis Challenged
Inflammatory and fibrotic diseases
- Tonix Pharmaceuticals (TNXP)Thesis Challenged
Autoimmune diseases
- TScan Therapeutics (TCRX)Thesis Challenged
Ankylosing spondylitis
- Viridian Therapeutics (VRDN)Thesis Intact
Autoimmune disease, Autoimmune disorders
- Zura Bio (ZURA)Thesis Intact
Systemic sclerosis, Polymyalgia rheumatica, Diffuse cutaneous systemic sclerosis
Drug pages
Obecabtagene autoleucel (obe-cel)Mivocabtagene autoleucel (miv-cel)
Upcoming catalysts
Firm dates · a specific day set by the company or regulator
Next 30 days
- Nov 8in 14 daysVelinotamig · Phase 1 results · Autoimmune diseases
- Nov 18in 24 daysAI-Immunology · Results · Autoimmune diseases
Later
- Mar 16in 142 daysAnaphylm · FDA decision · Anaphylaxis
Estimated timing · a month, quarter, half-year or year-end the company gave
Expected in December 2026
- December 2026CLN-978 · Results · Rheumatoid arthritis
Expected in Q4 2026
- Q4 2026ATI-9494 · IND submission · Immuno-inflammatory diseases
- Q4 2026Obe-cel · Phase 1 long-term results (CARLYSLE) · Systemic lupus erythematosus
- 4Q 2026Rese-cel · Pivotal trial start (RESET-SSc) · Systemic sclerosis · interstitial lung disease
- Q4 2026YUTREPIA · Phase 2a start (RE-WARM) · Raynaud's phenomenon associated with systemic sclerosis (SSc-RP)
- Q4 2026Tibulizumab · Phase 2 start (NEXUS-PMR) · Polymyalgia rheumatica
Expected in H2 2026
- H2 2026AlloNK · Phase 3 start · Refractory rheumatoid arthritis
- H2 2026COYA 303 · Results · Inflammatory diseases · preclinical
- H2 2026Zugo-cel · Phase 1 updated results · Autoimmune disease · B-cell malignancies
- 2H 2026IMVT-1402 · Pivotal results · Difficult-to-treat rheumatoid arthritis
- H2 2026VRDN-008 · Phase 1 results · Autoimmune disease
Expected by end of 2026
- Late 2026 or early 2027Izicopan · Phase 2 start · ANCA-associated vasculitis
- end of 2026KPL-1161 · Phase 1 start · IL-1-mediated disease
Expected in February 2027
- February 2027YUTREPIA · Phase 2a topline results (RE-WARM) · Raynaud's phenomenon associated with systemic sclerosis (SSc-RP)
Expected in Q1 2027
- Q1 2027Anaphylm · CTA submission · Anaphylaxis
- Q1 2027KP-701 · IND submission · Autoantibody-mediated disorders
Expected by end of March 2027
- early 2027Velinotamig · Phase 1/2a start · Autoimmune cytopenias · ITP/AIHA
- Early 2027TNF inhibitor · Trial start · Rheumatoid arthritis · psoriasis · inflammatory bowel disease
Expected in H1 2027
- H1 2027Nebokitug · Phase 2 start · Rheumatoid arthritis
- H1 2027PM359 · BLA submission · Chronic granulomatous disease · p47phox deficiency
- H1 2027Tibulizumab · Phase 2 results (TibuSURE) · Systemic sclerosis
Expected in Q3 2027
- Q3 2027KP-701 · Phase 1 results · Autoantibody-mediated disorders